Biotech announced that it has recently received the “Notice of Acceptance” approved and issued by the State Drug Administration regarding the marketing license application for the company's drug currently under development, verasitamab injectable drugs. This drug is a class 1 biological product for treatment. The indication is neovascular age-related macular degeneration. BAT5906 is an innovative recombinant humanized monoclonal antibody independently developed and produced by Baiaotai. It is an IgG1 full-length antibody with a molecular weight of 149 kDa. It can bind specifically with human VEGF-A165 and inhibit angiogenesis.

Biotech announced that it has recently received the “Notice of Acceptance” approved and issued by the State Drug Administration regarding the marketing license application for the company's drug currently under development, verasitamab injectable drugs. This drug is a class 1 biological product for treatment. The indication is neovascular age-related macular degeneration. BAT5906 is an innovative recombinant humanized monoclonal antibody independently developed and produced by Baiaotai. It is an IgG1 full-length antibody with a molecular weight of 149 kDa. It can bind specifically with human VEGF-A165 and inhibit angiogenesis.